alendronate has been researched along with Connective Tissue Diseases in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this preliminary study, we evaluated the effect of an oral bisphosphonate (alendronate) on bone mass in children with diffuse connective tissue diseases." | 9.09 | Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. ( Bardare, M; Bianchi, ML; Boncompagni, A; Brandi, ML; Cimaz, R; Corona, F; Falcini, F; Galbiati, E; Giuntini, D; Lepore, L; Luisetto, G; Picco, P; Zulian, F, 2000) |
| " In this preliminary study, we evaluated the effect of an oral bisphosphonate (alendronate) on bone mass in children with diffuse connective tissue diseases." | 5.09 | Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. ( Bardare, M; Bianchi, ML; Boncompagni, A; Brandi, ML; Cimaz, R; Corona, F; Falcini, F; Galbiati, E; Giuntini, D; Lepore, L; Luisetto, G; Picco, P; Zulian, F, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianchi, ML | 1 |
| Cimaz, R | 1 |
| Bardare, M | 1 |
| Zulian, F | 1 |
| Lepore, L | 1 |
| Boncompagni, A | 1 |
| Galbiati, E | 1 |
| Corona, F | 1 |
| Luisetto, G | 1 |
| Giuntini, D | 1 |
| Picco, P | 1 |
| Brandi, ML | 1 |
| Falcini, F | 1 |
| Stuart, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.[NCT01812551] | Phase 3 | 171 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alendronate and Connective Tissue Diseases
| Article | Year |
|---|---|
Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children.
Topics: Adolescent; Alendronate; Child; Child, Preschool; Connective Tissue Diseases; Humans; Osteoporosis | 2002 |
1 trial available for alendronate and Connective Tissue Diseases
| Article | Year |
|---|---|
Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study.
Topics: Adolescent; Alendronate; Body Height; Bone Density; Child; Child, Preschool; Connective Tissue Disea | 2000 |